Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) YoY EBITDA Growth: -1.05% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:JCARE Joincare Pharmaceutical Group Industry Co Ltd XSWX:JCARE
80 GF Score
Price $8.00
GF Value $9.20
! 3 Warning Signs
View Full Analysis

What is Joincare Pharmaceutical Group Industry Co YoY EBITDA Growth?

Joincare Pharmaceutical Group Industry Co XSWX:JCARE 80 YoY EBITDA Growth is -1.05% as of Mar. 2026. GuruFocus rates XSWX:JCARE with a GF Score™ of 80/100 and a GF Value™ of $9.20. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Joincare Pharmaceutical Group Industry Co's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was -1.05%.

Joincare Pharmaceutical Group Industry Co's EBITDA per Share for the three months ended in Mar. 2026 was $0.85.

Joincare Pharmaceutical Group Industry Co YoY EBITDA Growth Related Terms

Joincare Pharmaceutical Group Industry Co YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Joincare Pharmaceutical Group Industry Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Joincare Pharmaceutical Group Industry Co YoY EBITDA Growth Chart

Joincare Pharmaceutical Group Industry Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.49 12.90 2.71 -3.95 0.24

Joincare Pharmaceutical Group Industry Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 8.39 0.16 -30.31 -1.05
XSWX:JCARE
80GF Score
Joincare Pharmaceutical Group Industry Co Ltd XSWX:JCARE
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Joincare Pharmaceutical Group Industry Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Joincare Pharmaceutical Group Industry Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(3.315-3.307)/ | 3.307 |
=0.24 %

Joincare Pharmaceutical Group Industry Co's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(0.846-0.855)/ | 0.855 |
=-1.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -1.05% mean?
Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) has a YoY EBITDA Growth of -1.05% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Joincare Pharmaceutical Group Industry Co and its competitors.
Is Joincare Pharmaceutical Group Industry Co's YoY EBITDA Growth too high?
Joincare Pharmaceutical Group Industry Co's current YoY EBITDA Growth is -1.05%. Overall, Joincare Pharmaceutical Group Industry Co has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Joincare Pharmaceutical Group Industry Co's YoY EBITDA Growth compare to ZTS?
Joincare Pharmaceutical Group Industry Co's YoY EBITDA Growth of -1.05% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Joincare Pharmaceutical Group Industry Co and its competitors. Joincare Pharmaceutical Group Industry Co's current YoY EBITDA Growth is -1.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joincare Pharmaceutical Group Industry Co stock overvalued right now?
Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) has a current YoY EBITDA Growth of -1.05%. The stock's GF Value™ is $9.20, compared to a current price of $8.00 — trading 13% below its estimated fair value. The current YoY EBITDA Growth is -1.05%. Joincare Pharmaceutical Group Industry Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Joincare Pharmaceutical Group Industry Co (XSWX:JCARE), the current YoY EBITDA Growth is -1.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Joincare Pharmaceutical Group Industry Co (XSWX:JCARE) Overvalued in 2026?

Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co stock appears to be undervalued. The current stock price of $8.00 is trading 13% below its estimated GF Value™ of $9.20.

Key valuation signals for XSWX:JCARE:

  • YoY EBITDA Growth: -1.05%
  • GF Value™: $9.20 vs. price of $8.00 (13% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the XSWX:JCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Joincare Pharmaceutical Group Industry Co Business Description

Other Exchanges 600380:China
Address No. 17, Langshan Road, North District, High-tech Zone, Nanshan District, Guangdong, Shenzhen, CHN, 518057
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
80GF Score

Get the complete analysis for XSWX:JCARE

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.00
Price
$9.20
GF Value